Alterations in epigenomic patterns are associated with diverse physiological functions and pathological mechanisms causing aging-related diseases, such as degenerative disorders and cancers. We investigated the senescent effects of BIX01294, a G9a (histone methyltransferase) inhibitor, in human bone marrow mesenchymal stromal cells (hBM-MSCs). We determined the optimal dose and time of BIX01294 treatment in hBM-MSCs to be 1 μM and 12 h, respectively. Under these conditions, the expression of the antisenescent genes TERT, bFGF, VEGF, and Oct-4 increased, whereas the expression of the senescent factors p16, p21, and p53 decreased. The number of β-galactosidase-positive cells decreased significantly, and the rates of migration and cellular protection against oxidative damage increased in BIX01294-treated MSCs. These data indicate that an optimized dose of BIX01294 may improve the potency and senescence of stem cells, which may improve the efficacy of stem cell therapy.
AHN, MIN-JI; Jeong, Sin-Gu; and CHO, GOANG WON
"Antisenescence activity of G9a inhibitor BIX01294 on human bone marrow mesenchymal stromal cells,"
Turkish Journal of Biology: Vol. 40:
2, Article 17.
Available at: https://journals.tubitak.gov.tr/biology/vol40/iss2/17